Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Patho... - PubMed - NCBI

Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Patho... - PubMed - NCBI

Arch Pathol Lab Med. 2017 Feb 6. doi: 10.5858/arpa.2016-0554-CP. [Epub ahead of print]

Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology.

Sepulveda AR1, Hamilton SR2, Allegra CJ3, Grody W4, Cushman-Vokoun AM5, Funkhouser WK6, Kopetz SE7, Lieu C8, Lindor NM9, Minsky BD10, Monzon FA11, Sargent DJ12, Singh VM13, Willis J14, Clark J15, Colasacco C16, Bryan Rumble R17, Temple-Smolkin R18, B Ventura C16, Nowak JA19.

Author information

Abstract

OBJECTIVES:

-To develop evidence-based guideline recommendations through a systematic review of the literature to establish standard molecular biomarker testing of colorectal cancer (CRC) tissues to guide epidermal growth factor receptor (EGFR) therapies and conventional chemotherapy regimens.

METHODS:

-The American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology convened an expert panel to develop an evidence-based guideline to establish standard molecular biomarker testing and guide therapies for patients with CRC. A comprehensive literature search that included more than 4,000 articles was conducted.

RESULTS:

-Twenty-one guideline statements were established.

CONCLUSIONS:

-Evidence supports mutational testing for EGFR signaling pathway genes, since they provide clinically actionable information as negative predictors of benefit to anti-EGFR monoclonal antibody therapies for targeted therapy of CRC. Mutations in several of the biomarkers have clear prognostic value. Laboratory approaches to operationalize CRC molecular testing are presented.

PMID:

 

28165284

 

DOI:

 

10.5858/arpa.2016-0554-CP

[PubMed - as supplied by publisher]

Cancer Genomics

- Cancer PHGKB -

From Guideline Database

This database contains updated guidelines, policies and recommendations on genomic research and practice, as provided by professional organizations, federal advisory groups, expert panels and policy groups.

---

• The UK NEQAS for Molecular Genetics scheme for gastrointestinal stromal tumour: findings and recommendations following four rounds of circulation.  
  Published 2012 (United Kingdom National External Quality Assessment Service (UK NEQAS))
• Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results.  
  Published 2008 (International Agency for Research on Cancer (IARC))
• Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology.  
  Published 2017 (American Society for Clinical Pathology (ASCP)) (College of American Pathologists (CAP)) (American Society of Clinical Oncology (ASCO)) (Association for Molecular Pathology )
• Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and the American Society of Clinical Oncology.  
  Published 2017 (American Society for Clinical Pathology (ASCP)) (College of American Pathologists (CAP)) (Association for Molecular Pathology (AMP)) (Association for Molecular Pathology (AMP))
• NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017.  
  Published 2017 (National Comprehensive Cancer Network)

more